Earnings call transcript: Esperion Therapeutics Q2 2025 beats forecasts, stock rises

Esperion Therapeutics Inc. (market cap: $335 million) reported better-than-expected earnings for the second quarter of 2025, with a notable earnings per share (EPS) surprise and strong revenue figures. The company’s EPS stood at -$0.02, significantly surpassing the forecasted -$0.14, resulting in an 85.71% positive surprise. Revenue reached $82.4 million, exceeding the projected $63.54 million by 29.67%. Following the earnings announcement, Esperion’s stock surged 10.4% in pre-market trading, reflecting positive investor sentiment. According to InvestingPro data, analyst price targets for the stock range from $1.50 to $16.00, suggesting significant potential upside.

[Get access to 7 more exclusive InvestingPro Tips for Esperion and discover crucial insights about the company’s financial health and growth prospects.]

Key Takeaways

• Esperion’s EPS beat expectations with a significant positive surprise.
• Revenue exceeded forecasts, driven by strong growth in U.S. net product revenue.
• The stock price rose 10.4% in pre-market trading following the earnings report.
• The company anticipates sustainable profitability by 2026.
• Esperion is expanding its international partnerships and marketing efforts.

Company Performance

Esperion Therapeutics demonstrated a robust performance in Q2 2025, with total revenue increasing by 12% year-over-year to $82.4 million, maintaining its trailing twelve-month revenue growth rate of 13%. The growth was primarily driven by a 42% rise in U.S. net product revenue to $40.3 million, with a healthy gross margin of 47.8%. This marks the first quarter of operating income from ongoing business, approximately $15 million, highlighting the company’s operational improvements. Despite a 7% decline in collaboration revenue, Esperion is strategically expanding its market presence through international partnerships, though InvestingPro analysis indicates the company is currently operating with a significant debt burden, with total debt to capital ratio at 67%.

Financial Highlights

• Revenue: $82.4 million, up 12% year-over-year
• U.S. Net product revenue: $40.3 million, up 42% year-over-year
• EPS: -$0.02, beating the forecast of -$0.14
• Cash and cash equivalents: $86.1 million

Earnings vs. Forecast

Esperion’s actual EPS of -$0.02 significantly outperformed the forecasted -$0.14, indicating an 85.71% positive surprise. Revenue also exceeded expectations, with actual figures at $82.4 million compared to the forecast of $63.54 million, marking a 29.67% surprise. This performance is a positive deviation from previous quarters, where earnings often aligned closely with forecasts.

Market Reaction

Following the earnings release, Esperion’s stock price increased by 10.4% in pre-market trading, reaching $1.63. This surge reflects investor optimism fueled by the company’s strong financial performance and encouraging forward guidance. With a beta of 0.82, the stock traditionally shows lower volatility than the broader market. The stock’s movement places it closer to its 52-week high of $3.94, indicating renewed investor interest. Based on InvestingPro’s Fair Value analysis, the stock appears to be trading above its intrinsic value.

Outlook & Guidance

Esperion aims for sustainable profitability by 2026, leveraging its growing market presence and product portfolio. The company expects continued double-digit script growth and anticipates up to $120 million in milestone payments from Otsuka. Strategic initiatives include launching consumer TV ads and expanding international partnerships.

Executive Commentary

CEO Sheldon Koenig emphasized the company’s transformative impact on cardiovascular disease prevention, stating, "We are not just growing, we are transforming the landscape of cardiovascular disease prevention for underserved patients." He also highlighted the company’s profitability trajectory, noting, "We are on a path to sustainable profitability beginning in 2026."

Risks and Challenges

• Market Saturation: Competition in the statin-intolerant market could impact growth.
• Regulatory Changes: Potential shifts in healthcare regulations may affect operations.
• Economic Conditions: Macroeconomic pressures could influence consumer spending.
• R&D Expenses: Continued investment in research may strain financial resources.
• International Expansion: Challenges in global markets could affect growth plans.

Q&A

During the earnings call, analysts inquired about Esperion’s competitive landscape and product differentiation. The company addressed expectations for milestone payments and discussed trends in gross margin and R&D expenses. Analysts also explored the potential for Esperion’s products to reach blockbuster status, indicating strong interest in its growth prospects.

Full transcript - Esperion Therapeutics Inc (ESPR) Q2 2025:

Conference Operator: Hello, ladies and gentlemen, thank you for standing by, and welcome to Experian’s Second Quarter twenty twenty five Financial Results. At this time, all participants are in a listen only mode. Following the presentation, there will be a question and answer session. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to Alina Venezia, Head of Investor Relations for Experion Therapeutics.

Please go ahead.

Alina Venezia, Head of Investor Relations, Experion Therapeutics: Thank you, operator. Good morning, and welcome to Experion’s second quarter twenty twenty five earnings conference call. With us on today’s call are Sheldon Koenig, President and CEO and Ben Halliday, CFO. Other members of the executive team will be available for Q and A following our prepared remarks. We issued a press release earlier this morning detailing the content of today’s call.

A copy can be found on the investor page of our website together with a copy of the presentation that we will also be referencing. I want to remind callers that the information discussed on today’s call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward looking statements. Actual results could differ materially from those stated or implied by our forward looking statements due to the risks and uncertainties associated with the business. These forward looking statements are qualified in their entirety by the cautionary statements contained in today’s press release and in our SEC filings.

The content of this conference call contains time sensitive information that is only accurate as of the date of this live broadcast, 08/05/2025. We undertake no obligation to revise or update any forward looking statements to reflect events or circumstances after the date of the conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We will begin the call with prepared remarks and then open the line for your questions. I’ll now turn the call over to you, Sheldon.

Sheldon Koenig, President and CEO, Experion Therapeutics: Thank you, Alina. Good morning, everyone, and thank you for joining us. We’re thrilled to report a standout second quarter that delivered double digit sequential growth, more than 42% year over year gains in U. S. Net product sales and our first quarter of operating income from ongoing business.

These results reflect accelerating clinical adoption of NEXLETOL and NEXLASET fueled by our sharpened commercial execution, strong payer alignment and our ongoing targeted promotional strategy that’s resonating with the statin intolerant community. Total revenue for the second quarter twenty twenty five grew 12% year over year to $82,400,000 Looking at our strong U. S. Performance, where we saw a return to sequential double digit quarterly prescription and revenue growth, U. S.

Net product revenue grew 42% year over year to $40,300,000 and grew 15% sequentially from the 2025. Given our strong performance, we achieved operating income from ongoing business of approximately $15,000,000 giving us confidence that with continued global growth, we expect to transition to sustainable profitability beginning in the 2026. As we shared on our last call, the endorsement of NEXLETOL NEXLASET from leading cardiovascular professional societies was a powerful validation of our science and it’s already translated into action. Later this month, we look forward to the European Society of Cardiology updating their lipid management guidelines at the society’s annual meeting where we expect to be included in these updates. Turning to the progress we made on a number of our core marketing initiatives, including our campaign to reach patients who are statin intolerant, our tagline, Can’t take a statin, make NexoZet happen, was well received and this catchy phrase supported increased brand awareness among our target audience.

In fact, during the second quarter alone, we had more than 650,000 visits to our new consumer statin intolerance website and more than 600,000 click throughs to our physician site underscoring the impact of this successful campaign. We are implementing the right balance of in person and digital outreach and are pleased to report that 23% or nearly one quarter of our prescriptions were written by physicians with only digital touch points. In addition, our prescriptions coming from new writers, 38% were driven by digital only touch points. This highlights the importance of our digital omni channel programs and underscores the impact they can continue to have. We remain committed to building on these successful programs and are confident in their continued contribution to our growth.

Our expanded U. S. Field reimbursement manager support team made great strides in supporting our growing prescriber base by educating over 1,100 target prescribers Nexital and Nexlazet’s favorable reimbursement landscape. This was evident by an increase in all targeted prescriber approval rates over 80%. Combined with further expanded payer coverage, reductions in prior authorization requirements, increased reimbursement support resources and our appropriate balance of direct and digital marketing efforts, we believe we have significantly improved the access environment for patients and physicians alike, which resulted in a 10% increase in total retail prescription equivalents from this 2025 and increase our total prescriber base to more than 28,000 healthcare practitioners.

This momentum validates the growing confidence among clinicians and the expanding role of our therapies in addressing the unmet needs of statin intolerant patients. Our consumer marketing program featuring the lipid lurkers tackles the challenge of high cholesterol, a silent but serious threat by transforming it into mischievous characters that demand attention, which may be quietly lurking without their knowledge. Rather than relying on fear tactics, the lurkers personify LDL cholesterol’s hidden dangers, making the risk tangible and manageable without intimidation. This fresh compelling approach reshapes how patients perceive and address their cardiovascular risk. By blending engagement with patient empowerment, the campaign stood out in a crowded market, driving awareness and action for proactive cholesterol management with Nexletol and Nexlazette, the next step after statins.

This campaign has won the prestigious Med Ad News Best Consumer Digital campaign and is nominated for several more awards this year. Moving forward, we plan to launch a consumer television ad later in the year that will stream on connected TV such as Hulu and NBC Sports. These branded ads are expected to broaden awareness of statin intolerance and will feature our award winning lipid lurkers. The combined strength of the statin intolerance and lipid lurkers campaign coupled with improving payer dynamics support our continued growth now and into the future. Speaking of future growth, we remain committed to Experion’s continued growth in cardiovascular risk reduction with our plans to develop a triple combination product.

This therapy has the potential to be the most effective oral LDL cholesterol lowering option and to rival both existing injectables and emerging oral therapies. Development remains on track. In addition, our business development efforts are progressing nicely as we evaluate a number of potential opportunities to in license or acquire synergistic products to leverage our existing commercial infrastructure. We look forward to updating you on progress here as it unfolds. Additionally, we reached important settlement agreements with Three generic manufacturers have agreed not to market a generic version of Nexlitol in The United States prior to 02/1940.

We continue to identify opportunities to strengthen our intellectual property position and look forward to updating you on our progress. Turning to our pipeline where our strategy is to expand into high need, high value indications that highlight the broader potential of our novel ACLY biology, we continue to make progress advancing IND enabling studies to support our recently introduced program targeting primary sclerosing cholangitis known as PSC. PSC is a rare progressive liver disease with no approved therapies and represents a major unmet need with an estimated $1,000,000,000 annual market opportunity. We look forward to completing these studies and to filing an IND and potentially initiating first in human studies in the 2026. Throughout the second quarter, we and our international partners continued to make tremendous progress across a number of key geographies.

Our European partner, Daiichi Sankyo Europe continues to expand their reach of NILEMBO and UCENDY to benefit patients at the risk of cardiovascular disease who cannot manage their LDL cholesterol levels. Our royalty revenue from DSC increased 30% from the 2025 to $13,600,000 in the 2025. We are also thrilled to report that DSC has surpassed the 500,000 patient mark for patients who have been treated with our therapies in Europe, half a million patients. This is a meaningful milestone that reinforces confidence in our ability to build a similarly sized market in The U. S.

Throughout the first half of the year, we continue to advance multiple processes for the technology transfer for manufacturing of the Nalemso and Ustendi to DSE with various working capital benefits expected in 2025. Our Japanese partner, Otsuka Pharmaceuticals submitted for approval of our pemphotoic acid products in Japan for LDL cholesterol lowering and remain on track for approval and national health insurance pricing in the 2025. Upon this achievement, we expect to receive milestone payments of up to $120,000,000 The Japanese market is the world’s third largest cardiovascular prevention market and we believe the royalties on Japanese product sales will be a major revenue contributor over time. Building on our global progress, we expanded our international reach through a commercial partnership with ATLS Therapeutics, giving them the exclusive rights to commercialize NEXLETOL and NEXLIZET in Canada. Our previously filed new drug submissions to Health Canada are on track for review and we continue to expect market approval in the 2025.

Our partner in Israel, NeoPharm Israel remains on track for market approval of Nexletol and Nexletol in the 2026. And CSL Sequirus, our partner in Australia and New Zealand filed a marketing application in Australia for Nexletol and Nexletol in July 2025 and expects market approval Q4 twenty twenty six. The progress with these international partnerships is expected to deliver a consistent cadence of approvals and product launches over the coming months and year that will also provide a growing royalty stream and milestone payments, all of which support our strategic focus to drive revenue growth and profitability. With that overview of the business, let me turn the call over to Ben for a detailed review of our financial progress during the second quarter. Ben?

Ben Halliday, CFO, Experion Therapeutics: Thank you, Sheldon. Good morning, everyone, and thank you for joining us. I’m extremely excited and proud to share our financial results today. Our second quarter twenty twenty five financial results can be found in the press release we issued this morning and more detail will be included in our upcoming 10 Q. As you’ve heard Sheldon discuss, we had an exceptional second quarter highlighted by our first quarter of operating income from ongoing business in the company’s history, which sets us up nicely and supports our plans to transition to sustainable profitability starting in the 2026.

We are proud of the progress we’ve made and underscores our long held assertion that incremental growth when compounded and expanded will drop to the bottom line. Over time, this gives us considerable leverage as we move forward with confidence. Turning now to the financial results. Second quarter twenty twenty five total revenue was $82,400,000 up 12% from the comparable period in 2024. Note, this impressive growth was achieved even when compared to second quarter twenty twenty four during which we received a $25,000,000 one time milestone payment, further highlighting the strength of our underlying business.

U. S. Net product revenue was $40,300,000 compared to $28,300,000 for the comparable period in 2024, an increase of approximately 42%. Sequential quarterly net revenue growth was 15%. Collaboration revenue was $42,100,000 compared to $45,500,000 for the comparable period in 2024, a decrease of approximately 7% driven by the settlement agreement milestone with DSC received in the three months ended 06/30/2024, offset partially by increases in royalty sales with our partner territories and product sales for our collaboration partners from our supply agreements.

Excluding the settlement agreement milestone, collaboration revenue grew 105% from the comparable period. Turning to the rest of the P and L. For the second quarter twenty twenty five, research and development expenses were $7.2500000.0 dollars for the comparable period of 2024, a decrease of 37%. Selling, general and administrative expenses were $39,500,000 compared to $44,200,000 for the comparable period in 2024, a decrease of 11%. The decrease quarter over quarter was primarily related to decreased media and marketing costs.

We are reiterating our full year 2025 operating expense guidance, which is expected to be approximately $215,000,000 to $235,000,000 including $15,000,000 in non cash expenses related to stock compensation. We are on our way to transitioning to sustainable profitability starting in 2026 and our operating income from ongoing business in the second quarter validates those expectations. We ended the quarter with cash and cash equivalents of $86,100,000 which combined with our excellent operational results and continued global growth well positions us to create value and achieve our goals. With that, I will now turn the call back over to

Sheldon Koenig, President and CEO, Experion Therapeutics: Sheldon for closing remarks. Sheldon? Thank you, Ben. As you’ve heard today, have yet again delivered strong results and are executing with precision and building meaningful momentum across every dimension of our business from commercial performance and clinical adoption to global expansion and pipeline innovation. We are not just growing, we are transforming the landscape of cardiovascular disease prevention for underserved patients.

With Nexletol and Nexlezet, we are delivering real world impact. And with every new prescriber, every new patient reached and every new market entered, we are advancing our mission to reduce cardiovascular risk on a global scale. Looking ahead, we are energized by the opportunities in front of us. Our international partnerships are poised to unlock new revenue streams and our pipeline is expanding into high value areas of unmet need with the potential to shape the future of care. When you combine all these factors with diligent expense management, we are on a path to sustainable profitability beginning in the 2026 and remain deeply committed to creating long term value for our shareholders, our partners and most importantly for the patients we serve.

Thank you for your continued support and belief in our vision. We look forward to updating you on our continued progress next quarter. At this time, we are ready for questions.

Conference Operator: Thank you so much. That comes from Serge Belanger with Needham. Please proceed.

Serge Belanger, Analyst, Needham: Hi, good morning and congrats on progress this quarter. A couple of quick questions on naxitol and exelbit. Can you remind us how many remaining prior auths are relative to the TAM for the product? And I think you mentioned you had over 80% approval rate for these prior auths. Is that a number you expect to continue improving on?

And secondly, for Ben, I think you mentioned you expect some of the working capital benefits from transfer to DSC to start occurring later, this year. Just curious what that will look like, on the balance sheet when it starts coming together. Thank you.

Sheldon Koenig, President and CEO, Experion Therapeutics: Great, Vijay? Yeah, Serge, how

Vijay, Unnamed Executive, Experion Therapeutics: are you? As far as the approval rates, as Sheldon had mentioned, in less than sixty days with the new field reimbursement team, they’ve hit 1,100 targets in those sixty days, and we’re showing rates well over 80%. We have certain pacesetter regions that are even higher than 80%. But as you know, with our approval rates, like CVS, where we had our prior authorizations removed, we’ve hit an all time high there at hitting 93% approval rates there, Aetna 94%. And overall, we’re well over 80%.

But we have the certain key places where we’ve negotiated those prior authorizations really, and improved that criteria. We’re at 92,000,000 lives updated or 192,000,000 lives, excuse me, aligned to our new label. And we continue to just see these approvals increasing day after day.

Ben Halliday, CFO, Experion Therapeutics: Thanks, Serge. This is Ben. Thanks for the question. On the working capital side, this is just in line with what we’ve been emphasizing on the importance from the tech transfer, right? We have a long time long production timeline with our product.

And so, as DSE takes over, we will start to ramp down inventory production on our side, which we expect to happen towards the second half of this year. So I would inventory will come down as we start working through that backlog, and they will start ramping up in 2026.

Vijay, Unnamed Executive, Experion Therapeutics: Thank you.

Conference Operator: Thank you. Our next question is from Kristen Klauska with Cantor Fitzgerald. Please proceed.

Kristen Klauska, Analyst, Cantor Fitzgerald: Hi, good morning. Congrats on a strong quarter. So if I look at the graph on slide 10, where you talk about growth, can you it looks like the jump from April to May was probably the largest numerical gain in the two point five years. So if you can I know you talked about several growth levers, but what in particular really like stood out during that transition time?

Sheldon Koenig, President and CEO, Experion Therapeutics: Thanks, Kristen. I think really for us it’s really been our strategy. We’ve talked a lot today about going after statin intolerant patients and really establishing this beachhead, which has really continued to drive growth and create a significant amount of awareness. I think what you’ve heard today also is our plans as we move forward. You heard our tagline, can’t take a statin, make Nexlazette happen.

We’ve got representatives out there that are promoting that. We have a lot of material that shows that asking the question, can you take a statin? So to me, I think that’s what’s really continuing to drive the growth. I also have Lisa Schaefer, who is our head of marketing in The US also provide some comments.

Lisa Schaefer, Head of US Marketing, Experion Therapeutics: Yep, absolutely. And we see the strong growth both from Medicare and commercial, which was really great, and also with primary care physicians and cardiologists. So, it really was just sustained growth quarter over quarter. But the out of pocket expense for Medicare patients has really improved in the second quarter as they reach that deductible. So, that really will be tailwinds for the rest of the year as well.

Kristen Klauska, Analyst, Cantor Fitzgerald: Okay, thanks for that. So, with the growth of the new prescribers that are coming on board, is the number one selling point essentially that they have an option for these statin tolerant patients? I guess what would you rank maybe as the number two and number three selling points then primary prevention, secondary or anything else in particular that’s really standing out as the other two selling points? Thanks so much again.

Lisa Schaefer, Head of US Marketing, Experion Therapeutics: Yes, absolutely. So, the fact that Nexletol and Nexlazet are the only products indicated for reducing CB events in primary prevention is a very strong selling point. In addition, the only products that had the CB risk reduction, as you mentioned, in statin intolerant patients, no other product now or in the future is studying that population for CB risk reduction. So, those are really the strongest points that we have. Sheldon, anything to

Vijay, Unnamed Executive, Experion Therapeutics: add to that? Thanks.

Conference Operator: One moment for our next question, please. And it comes from Dennis Dink with Jefferies. Please proceed.

Dennis Dink, Analyst, Jefferies: Hi. Good morning. This is Georgia on for Dennis. Thanks for taking our questions. Two questions from us.

The first is, how do you view consensus US revenue for the year, which is around a 170, and the underlying script growth required to get there? When will you consider giving revenue guidance? And then our second question is, can you remind us on the cadence of milestone payments from Otsuka and are there very simple thresholds that need to be met? And the contact language is very clear. And then can you reiterate that there won’t be any confusion like we saw from Daiichi a few years ago?

Thanks.

Ben Halliday, CFO, Experion Therapeutics: Yeah. Hi. Thanks for the question. I’ll take those in two parts. So on the consensus side, yes, I think you can see that we’re tracking nicely and in line.

I think this was a good quarter in terms of beating consensus, and we’re tracking well ahead of where we would want to be for that. On the milestone side, I’ll reiterate, we have milestones in the second half with the Japanese regulatory process, which is up to $120,000,000 in milestone payments. We expect those to come, like I said, in the second half of the year. We’re confident we’re going to achieve that full amount based on the contract language. There are tiers and thresholds associated with it.

But looking and knowing what those are, I think we are in good shape to maximize the potential for those milestones.

Dennis Dink, Analyst, Jefferies: Okay. Thank you. And and on on the underlying script growth required to get there for the consensus, which is around $1.70?

Sheldon Koenig, President and CEO, Experion Therapeutics: We’re not. Georgia, we haven’t really disclosed what we’re doing. It falls in line with guidance. We haven’t really given financial guidance. We’re not giving script guidance.

But I think what’s important is to show and something we’ve talked about before is that we will continue to demonstrate double digit script growth, which we’ve done again this quarter with over 10% script growth. And we’re confident that that momentum will continue.

Dennis Dink, Analyst, Jefferies: Okay, thank you so much. Congratulations again.

Conference Operator: Thanks. Thank you. Our next question is from Jessica Fye with JPMorgan. Please proceed.

Jessica Fye, Analyst, JPMorgan: Hey, guys. Good morning. I have several questions this morning, mostly about the model and then kind of a bigger picture question. First, can you talk about the gross margin trend we should expect in the back half of the year and into ’26? Guess I had thought it would kind of start to materialize, but maybe not.

So just curious kind of how to think about the back half and then next year, and frankly, ultimately, you land. How should we think about gross to nets over the rest of this year? And then it looks like r and d, particularly after this quarter, is tracking below the 2025 r and d guidance. Should we expect a significant ramp up in r and d in the back half to kinda get you into that range? So those are the model questions.

And then the last one is just basically wanted to ask you to kinda make the case here that Nexletol will remain competitive in the non statin LDL space with additional oral mechanisms coming to market. Thank you.

Ben Halliday, CFO, Experion Therapeutics: Thanks, Jess. I will handle the very exciting model questions first and then turn it over to Sheldon for the competitor side. So, looking at the model, I think kind of going in order of what you asked about, on the gross margin side, the true benefits from the tech transfer will kick in, I think, early next year. This quarter was a good gross margin. I think it was largely in part due to the revenue mix as well as some of the underlying movement of materials that we had.

I But think it’s indicative of what we can expect once the tech transfer kicks in place and the beneficial margins we would see there. On gross to net, I think we’re in steady state at this point. We’ve seen two quarters of what a post IRA gross to net would look like and the lack of the Medicare coverage gap. And frankly, it’s been a huge tailwind for us over the course of this year. So we will not see that kind of compounding factor of gross to nets worsening over the course of the year.

And we will keep seeing the steady favorable gross to net, which you’ve seen so far in Q1 and Q2. On the R and D side, Q2 was light, but I think that’s mostly just a timing thing. We have our pediatric trial, which is beginning to ramp up and you’ll see in the second half, I would not use the word significant ramp up. R and D still remains pretty minimal in the grand scope of our spend, but you will see an increase compared to Q2 as that pediatric trial starts to ramp up in the second half of the year.

Sheldon Koenig, President and CEO, Experion Therapeutics: Great. Thanks, Ben. Hey, Jeff. Let me address your question as it relates to NEXLETOL and NEXLET being competitive into the future. And I’ll segment this in two ways.

We do these live now and actually our computers are updating while I was actually reading the script. So I want to reiterate one part of it. And that is from an IP perspective, we’ve already mentioned that we’ve had three of the ANDA filers settled to 02/1940. And that’s important because as you know, our baseline projections were always June 2031. And we’ve started to actually plan beyond that.

So we’re very confident as we stated before about our patent. And so from a future perspective, that’s going to allow us to continue to grow these products for a number of years. That’s one aspect. But the second aspect is more about what do we have today. We’re on the market today.

We are the only product that has studied statin intolerant patients. We are the only product that also has, as Lisa mentioned, an indication and primary prevention. No other future product is actually doing an outcome study, whether that be oral PCSK9 or CETP inhibition in primary prevention. Let’s also not forget there have been four CETP inhibitors that have failed previously, and it remains to be seen what happens with the CETP that’s in development. So we’re very confident based upon where we stand, really a summary of what we did today from a reimbursement perspective, how we’ve been able to drive growth, physicians becoming more aware of this product.

So very bright future ahead. And I’ve always said when this product becomes generic, it’s going to be the most utilized generic product ever in lipid lowering. Our mission is to make that goal now.

Conference Operator: Thank you. One moment for our next question that comes from Jason Semansky with Bank of America. Please proceed.

Ben Halliday, CFO, Experion Therapeutics: Good morning. Congrats on the quarter and thanks so much for taking our question. I guess Sheldon, maybe for you, at a high level, we appreciate it’s still early days in the launch and we’re certainly not overlooking the progress to date, but you’ve talked about potential of bempedoic acid reaching blockbuster status, and sort of comparing where we are, we’re curious, you know, what gets you there and when should we expect the inflection to occur, you know, particularly given the potential of competitive oral non statin agents entering and additional potential headwinds including reductions in MedicareMedicaid spend and so forth?

Sheldon Koenig, President and CEO, Experion Therapeutics: Yeah, so first of all, it kind of goes back to slide 10 of the presentation. We’ve seen an inflection. This is a big market. This is a TAM of 70,000,000 patients. This isn’t like an orphan rare, as you know, oncology product where you see this hockey stick take off.

It’s something that, a market that will continue to grow and you’ll continue to see the growth in our product. We’re very happy in where we stand. The fact that we’ve been able to provide double digit growth in basically every single metric that you look at. We think that to your point, early in the launch, we’ve got a long way to go. We’re just starting and we’re seeing tremendous gains.

As we mentioned today, Europe is a great bellwether as well, as we continue to maximize our label from the clear outcome study. As you know, Jason, we haven’t given guidance of when we’ll be at certain points. But I think you can see by our ongoing successful quarters, we’re going to get there. As it relates to future competition, as I mentioned previously, we really need to see what the outcomes data shows for these products. And they’re a long way off.

So I would actually ask you to ask them how they think that will look versus us in the future. Thank you.

Conference Operator: And we have a question from Joe Pantginis with H. C. Wainwright. Please proceed.

Alina Venezia, Head of Investor Relations, Experion Therapeutics0: Hey, everybody. Good morning. Thanks for taking the questions. I have two, please. So first, on the back end with regard to PSC and your plans, what would you consider any rate limiting steps that might potentially impact your 2026 guidance?

Ben Halliday, CFO, Experion Therapeutics: I mean, don’t really anticipate any, to be honest. Everything associated with our PSC program is baked in and incorporated into our expense guidance. And we’ve always reiterated this is a relatively cheap program to move forward through the IND process, which we expect to continue in the second half of the year.

Alina Venezia, Head of Investor Relations, Experion Therapeutics0: So that’s from an expense front also, like, say, from the scientific or preclinical study part components?

Ben Halliday, CFO, Experion Therapeutics: Oh, no, no, no, nothing this year.

Alina Venezia, Head of Investor Relations, Experion Therapeutics0: Okay, got it. And my second question, I will admit is somewhat rhetorical, but I would love your thoughts. So when you look at just The US, you talked about currently having about 28,000 healthcare providers prescribing the drug. Looking at your various marketing campaigns, the new ones coming up, the digital campaigns and what have you, what would you say would be the key inflection areas that would take you more quickly from 28,000 HCPs to say 50,000 versus say 28,000 to 29,000.

Sheldon Koenig, President and CEO, Experion Therapeutics: Yeah, well, look, I mean, I think it’s your point, Joe, we’ve been showing this growth every quarter as it relates to physicians increasing prescribing. I think what’s allowed us to do is also analyze what are the tactics getting us there. We talked about this TV ad and connected television. This is not a big DTC campaign. But this is something as more folks look at their phone or their tablet or their iPad, these are consumers and they’re watching whether that be Hulu or NBC Sports as we mentioned, there’ll be others.

Consumers being driven to the physician also is very helpful. Matter of fact, we’ve done market research that has shown that every time a consumer has asked for this drug they’ve gotten it. So this tactic of can’t take a statin, make NexoZet happen, that’s one that’s driving physician growth. The consumer activation will also drive growth. And what we’re also seeing is that physicians who use this drug in patients who can’t take a statin, whether they can’t take a statin at all or they can only take a low dose of a statin, they say, wow, if it works this well without even taking the statin, what would it be like if they were taking the statin?

So we’re seeing more adoption than that add on therapy also. And again, primary prevention is a big driver. So all of those levers are going to continue our growth. And again, I would remind folks that primary prevention is a lever. We own that airspace.

Nobody now or in the future will have that type of indication.

Alina Venezia, Head of Investor Relations, Experion Therapeutics0: Perfect, I love the thoughts. I appreciate that. And again, it’s just the growing strong blocking and tackling that you guys doing. Thanks for the answers.

Ben Halliday, CFO, Experion Therapeutics: Yes, sir.

Conference Operator: Thank you. And this concludes our Q and A session. I will turn it back to management for final comments.

Sheldon Koenig, President and CEO, Experion Therapeutics: Thank you, operator. And thank you all again for your time and attention this morning. We are looking forward to participating in a number of September conferences and hope to have the opportunity to connect with many of you then. In the meantime, if you have any questions or would like to have a call with the team, just reach out to our Head of Investor Relations, Alina Venezia, and have a great day and a great week. Take care.

Conference Operator: And this concludes our conference. Thank you all for participating and you may all disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.